Zacks Research Issues Optimistic Forecast for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Wednesday, January 14th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($1.95) for the quarter, up from their prior forecast of ($1.97). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q3 2026 earnings at ($1.93) EPS, Q4 2026 earnings at ($1.87) EPS, FY2026 earnings at ($7.60) EPS, Q1 2027 earnings at ($1.64) EPS, Q2 2027 earnings at ($1.71) EPS, Q3 2027 earnings at ($1.71) EPS, Q4 2027 earnings at ($1.63) EPS and FY2027 earnings at ($6.69) EPS.

Other analysts also recently issued reports about the company. Royal Bank Of Canada downgraded Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $57.00 to $28.00 in a research note on Wednesday, November 19th. The Goldman Sachs Group dropped their target price on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Leerink Partners increased their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright boosted their price objective on shares of Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.44.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $27.19 on Monday. The company has a market capitalization of $1.59 billion, a P/E ratio of -3.88 and a beta of 0.89. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00. The company’s fifty day moving average is $29.18 and its two-hundred day moving average is $35.49.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The firm had revenue of $12.88 million during the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period in the prior year, the company posted $16.22 earnings per share.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,932 shares of the stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the transaction, the insider owned 29,190 shares in the company, valued at $790,757.10. This trade represents a 9.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the sale, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 37,005 shares of company stock worth $1,064,531. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the first quarter worth $40,000. First Horizon Corp purchased a new position in shares of Agios Pharmaceuticals in the third quarter valued at $45,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 320 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth about $79,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth about $133,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.